曾昭沖，男，主任醫(yī)師，教授，現(xiàn)任復(fù)旦大學(xué)中山醫(yī)院放療科主任，1962年9月出生，博士研究生導(dǎo)師，2001年7月開(kāi)始主持中山醫(yī)院放射治療科工作至今。1986年福建醫(yī)科大學(xué)畢業(yè)。1989年考取腫瘤學(xué)家湯釗猷院士的碩士研究生，在中山醫(yī)院肝癌研究所從事肝癌的導(dǎo)向內(nèi)放療臨床工作， 這項(xiàng)工作在1996年榮獲科技成果三等獎(jiǎng)（第三完成者）。2003年獲首屆上海市醫(yī)學(xué)科技獎(jiǎng)3等獎(jiǎng)，2005年榮獲上海市第6屆臨床醫(yī)療成果2等獎(jiǎng)，2006年獲教育部科技成果一等獎(jiǎng)，均為完成者。2008年獲得科學(xué)技術(shù)進(jìn)步2等獎(jiǎng)（第三完成者）。作為作者或通訊作者在國(guó)外具有高影響因子的SCI醫(yī)學(xué)期刊發(fā)表論著20余篇，這些論著在肝癌放療領(lǐng)域得到同行的廣泛引用。1994年-1996年、1999年兩度赴美國(guó)學(xué)習(xí)，共計(jì)3年，在美國(guó)放射治療較高研究機(jī)構(gòu)RTOG（全美放射治療協(xié)作組）主席Curran醫(yī)生，和放射生物學(xué)家、國(guó)際放射研究學(xué)會(huì)主席Iliakis教授的共同指導(dǎo)下，學(xué)習(xí)放射生物學(xué)、內(nèi)外放療實(shí)驗(yàn)和臨床工作?；貒?guó)后，致力于肝癌的放射治療研究，論證肝癌屬于放射敏感腫瘤，開(kāi)創(chuàng)性地開(kāi)展肝癌患者淋巴結(jié)轉(zhuǎn)移、門(mén)脈/下腔靜脈癌栓、腎上腺轉(zhuǎn)移的放射治療，由此推動(dòng)人們對(duì)肝癌放射治療的重新認(rèn)識(shí)，這些論文在國(guó)際的放射治療專(zhuān)業(yè)雜志《國(guó)際放射腫瘤學(xué)??生物學(xué)?物理學(xué)》、《癌癥雜志》、《歐洲核醫(yī)學(xué)雜志》、《美國(guó)臨床腫瘤雜志》上發(fā)表。被《Cancer》、《International Journal of Radiation Oncology, Biology, Physics》、《American Journal of Clinical Oncology》等多家美國(guó)的腫瘤雜志邀請(qǐng)為審稿人，負(fù)責(zé)肝癌方面的評(píng)審。2001年被RTOG主席Curran醫(yī)生和放射生物學(xué)家Iliakis教授共同邀請(qǐng)為T(mén)homas Jefferson大學(xué)醫(yī)院放射腫瘤科客座教授。美國(guó)放射腫瘤學(xué)會(huì)（ASTRO）會(huì)員,抗癌協(xié)會(huì)臨床腫瘤協(xié)作委員會(huì)委員、上海市放療學(xué)會(huì)委員。作為作者在國(guó)外具有高影響因子的SCI醫(yī)學(xué)期刊發(fā)表論著13篇，這些論著在肝癌放療領(lǐng)域得到同行的廣泛引用。發(fā)表論著：（僅是于英文ＳＣＩ論文）。1. Zeng ZC, Zhang SM, Tang ZY, et al. Caffeine enhanced radiation-induced apoptosis in heptocellular carcinoma cell line. Cancer Clin Res (Peer-review). 2. Zeng ZC, Tang ZY, et al. Consideration of the role of radiotherapy for unresectable intrahepatic cholangiocarcinoma? — a retrospective ysis of 75 patients. Cancer J 2006；14(2):113-1223. Zeng ZC, Tang ZY, et al. Consideration of the role of radiotherapy for lymph node metastases in patients with HCC ─ A retrospective ysis for prognostic factors from 125 patients. Int J Radiation Oncology Boil Phys 2005:63(4):1067-10764. Zeng ZC, Tang ZY, et al. Radiation therapy for adrenal gland metastases from hepatocellular carcinoma. Jpn J Clin Oncol 2005；35（2）：61-675. Zeng ZC, Fan J, et al: A comparison of treatment combinations with and without radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombus. Int J Radiation Oncology Boil Phys 2005 ;61(2):432-4436. Zeng ZC, Tang ZY, et al: A comparison of chemoembolization combination with and without radiotherapy for unresectable hepatocellular carcinoma. Cancer J 2004;10:307-3167. Zeng ZC, Tang ZY, et al: Radiation therapy for the locoregional lymph node metastases from hepatocellular carcinoma, phase I clinical trial. Hepato-Gastroenterology2004;51:201-2078. Zeng ZC, Tang ZY, et al: Comparison between radioimmunotherapy and external beam radiation therapy for patients with hepatocellular carcinoma. Eur J Nucl Med 2002;29:1657-689. Zeng ZC, Jiang GL, et al: DNA-PKcs subunits in radiosensitization by hyperthermia on hepatocellular carcinoma Hep G2 cell line. World J Gastroenterol 2002;8:797-80310. Zeng ZC, Tang ZY, Wu ZQ, et al: Phase I clinical trial of oral Futulon and combined hepatic arterial chemoembolization and radiotherapy in unresectable primary liver cancers, including clinicopathological study. Am J Clinical Oncol 2000；23(5): 449-45411. Zeng ZC, Tang ZY, Liu KD, et al: Improved long-term survival for unresectable hepatocellular carcinoma (HCC) with a combination of surgery and intrahepatic arterial infusion of 131I-anti-HCC mAb. Phase I/II clinical trials. J Cancer Res Clin Oncol 1998;124(5):275-28012. Zeng ZC, Tang ZY, Liu KD, et al: Observation of changes of peripheral T lymphocyte subsets by flow cytometry in patients with liver cancer treated with radioimmunotherapy. Nucl Med Comm. 1995;16:378-38513. Zeng ZC, Tang ZY, Xie H, et al: Human anti-(Murine Ig) antibody responses in patients with hepatocellular carcinoma receiving intrahepatic arterial 131I-Hepama-1 mAb-Preliminary results and discussion. Cancer Immunology Immunotherapy 1994;39:332-33614. Zeng ZC, Tang ZY. Changes of serum alpha fetoprotein before and after radioimmunotherapy in patients with hepatocellular carcinoma. Chin J Cancer Res [English] 1994;6:83-9015. Zeng ZC, Tang ZY, Xie H, et al: Radioimmunotherapy for unresectable hepatocellular carcinoma using 131I-Hepama-1 mAb: preliminary results. J Cancer Res Clin Oncol 1993;119:257-25916. Geng CX, Zeng ZC, et al: Docetaxel inhibits SMMC-7721 human hepatocellular carcinoma cells growth and induces apoptosis. World J Gastroenterol 2003;9:696-70017. Wang H, Zeng ZC, Bui TA, et al. Efficient rejoining of radiation-induced DNA double-strand breaks in vertebrate cells deficient in genes of the RAD52 epistasis group. Oncogene. 2001；20(18):2212-2418. Wang H, Zeng ZC, Perrault AR, et al. Genetic evidence for the involvement of DNA ligase IV in the DNA-PK-dependent pathway of non-homologous end joining in mammalian cells. Nucleic Acids Res. 2001；29(8):1653-6019. Wang HC, Zeng ZC, Bui TA, et al: Nonhomologous End-Joining of Ionizing Radiation-induced DNA Double-Stranded Breaks in Human Tumor Cells Deficient in BRCA1 or BRCA2. Cancer Res 2001 ;61:270-27720. Cheong N, Zeng ZC, Iliakis G. Evidence for factors modulating radiation-induce G2-delay: potential application as radioprotectors. Physica Medica 2001;17(s):205-20921. Asaad NA, Zeng ZC, Iliakis G, et al: Homologous recombination as a potential target for caffeine radiosensitization in mammalian cells: reduced caffeine radiosensitization in XRCC2 and XRCC3 mutants. Oncogene 2000;19:5788-80022. Steven JD, Zeng ZC, Iliakis G, et al: DNA-dependent protein kinase stimulates an independently active, nonhomologous, end-joining apparatus. Cancer Res 2000;60:1245-5323. Hu B, Zhou XY, Wang X, Zeng ZC, Iliakis G, Wang Y. The radioresistance to killing of a1-5 cells derives from activation of the chk1 pathway. J Biol Chem. 2001；276(21):17693-8